BackInnoCan Pharma Overview

InnoCan Pharma EBIT

Latest ebit for INNO.CN: $-1.1M, below the sector sector average of $2.4T.

Get informed when a big investor buys or sells

+ Follow

Quarterly EBIT

-$495.10K
↓ 371.52% YoY

As of Jun 30, 2026

Annual EBIT (TTM)

-$1.11M
↓ 273.67% YoY

Trailing 12 months ending Jun 30, 2026

Average EBIT (Comparison Companies)

EBIT History

EBIT Comparison

Annual EBIT Growth Rate (%)

Annual EBIT Growth (Absolute)

InnoCan Pharma (INNO.CN) FAQ

The latest EBIT for INNO.CN is $-1.1M as of June 2026. That compares with $640K in the prior-year period — down 273.7% year over year. That is below the sector sector average of $2.4T. Investors often review this figure alongside InnoCan Pharma's historical trend and sector peers before judging valuation or financial health.

Over the past year, INNO.CN's EBIT moved from $640K to $-1.1M — a 273.7% year-over-year decrease. If the trend continues in the same direction for several quarters, it can signal a meaningful shift in InnoCan Pharma's operating scale or balance-sheet position.

Against its sector companies, INNO.CN currently prints $-1.1M for EBIT, while the sector average sits near $2.4T. That is roughly 100.0% below the sector mean. Large gaps often invite a closer look at InnoCan Pharma's growth, margins, and balance sheet.

A EBIT figure of $-1.1M for INNO.CN is a snapshot of scale on that line item. On its own it does not say whether the business is healthy — you also want growth rate, margins, and how the number compares with similar companies. The sector average is about $2.4T. Explore the charts below for those layers of context.

After noting INNO.CN's EBIT ($-1.1M), review year-over-year change from $640K, peer averages, and a few neighboring metrics such as revenue, margins, or valuation multiples. That combination usually beats staring at a single figure. The navigation links on this page jump you to those related views.

Questions & Answers